HUMA | tickerfilter.com

Fundamental analysis

28%

Profitability 0%

Dept financing 24%

Liquidity 58%

Performance 50%

Company vs Stock growth

N/A

6.650 5.780

-0.870 -13.08%

+ Add row to compare

Performance

5 Days

-14.81%

1 Month

-60.34%

3 Months

-75.05%

6 Months

-78.64%

1 Year

-62.17%

2 Year

-65.47%

Key data

Stock price

$1.15

P/E Ratio

0.00

DAY RANGE

$1.15 - $1.35

EPS

-$1.10

52 WEEK RANGE

$1.15 - $9.97

52 WEEK CHANGE

-$61.54

MARKET CAP

649.270 M

YIELD

N/A

SHARES OUTSTANDING

119.351 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-09-2025

BETA

0.58

PUBLIC FLOAT

AVERAGE 10 VOLUME

$7,024,954

AVERAGE 30 VOLUME

$5,436,649

Company detail

CEO: Laura E. Niklason
Region: US
Website: humacyte.com
Employees: 150
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues. Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company was founded in 2004 and is headquartered in Durham, North Carolina.

HUMA - Humacyte, Inc.